Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Novartis buys cancer specialist Endocyte for $2.1bn
It’s worth pointing out that buying Endocyte also gives Novartis an additional platform in CAR-T cancer immunotherapy to complement its current assets, including already-marketed therapy Kymriah (tisagenlecleucel) for
Latest news
-
Cancer disruptor F Star names next CEO
The co-administration of immunotherapies is expected to be the next cornerstone in cancer treatments.
-
A look ahead to key trial readouts at ESMO
Finally, other studies to look out for at ESMO cover the safety of immunotherapy for HIV patients with cancer, whether women and men experience the same side effects from chemotherapy, if
-
BMS finds a new immunotherapy partner with $12m Compugen deal
Combination with novel antibody targeting PVRIG pathway. Bristol Myers Squibb is continuing its tireless search for the perfect immunotherapy combination, today announcing a new $12m deal with Compugen. ... The Israel-based company’s lead candidate
-
CHMP delays decision on Kiadis’ GVHD immunotherapy
CHMP delays decision on Kiadis’ GVHD immunotherapy. Medicines regulator issues out Day 180 List of Outstanding Issues.
-
Three share Nobel chemistry prize for work on protein ‘evolution’
Earlier this week, the 2018 Nobel Medicine Prize was jointly won by James Allison of the University of Texas and Tasuku Honjo of Kyoto University for their work on cancer immunotherapy,
More from news
Approximately 68 fully matching, plus 377 partially matching documents found.
Latest Intelligence
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma. ... Open-minded culture. Like the new HQ’s
-
China: AstraZeneca’s new engine for growth and innovation
AZ isn’t a frontrunner overall in lung cancer immunotherapy – MSD consolidated its global lead by gaining a groundbreaking approval of Keytruda in China in July – but AZ has an ace
-
Chinese biotech’s global ambitions
The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and
-
Made in China
It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential
-
Cancer immunotherapy: What's on the horizon?
Cancer immunotherapy: What's on the horizon? Old and new therapies. Cancer remains one of the world’s top healthcare challenges, but over the years our ability to treat the disease ... and ovarian cancer, and some tumours such as pancreatic and
More from intelligence
Approximately 1 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints CCO, Stephen Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
-
Zelluna Immunotherapy appoints chief technology officer
Zelluna Immunotherapy appoints chief technology officer. Arjan Roozen will consolidate the biotech’s manufacturing strategy. ... Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
immunotherapy category.
More from appointments
Approximately 2 fully matching, plus 43 partially matching documents found.
Latest from PMHub
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
-
Training the next generation of biotech leaders
Technology born out of barcodes, tracking and scanning will become critical as we embrace things like cellular immunotherapies. ... From dream to reality. The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning
-
SWITCHED ONcology
SWITCHED ONcology. We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched ON. Switched ONcology is the
-
The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication
The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication.
-
Medical information in precision medicine
Immunotherapy 2.0. Treating patients down to the molecular level of their disease is incredibly exciting. ... The immunotherapy market is hypercompetitive. In the future, the challenge will be differentiating products in this space.
More from PMHub
Approximately 12 fully matching, plus 11 partially matching documents found.
Featured jobs
-
Scientific Team Lead
-
Competitive Salary
-
Account Director
-
Negotiable
-
Account Director - Digital
-
Great salary and benefits
-
Associate Medical Director
-
Highly Competitive
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Experienced Editor, London, Medical Communications
-
Competitive package
- Account Manager, Healthcare Advertising
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Associate Medical Director
-
Salary TBC
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Director Healthcare PR Communications
-
Salary TBC
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director – Global Healthcare PR
-
Salary TBC
Subscribe to our email news alerts
PMHub
Hayward Medical Communications
Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
Quick links
Infographics
